SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Results of Operations and Financial Condition
EX-99.1 2 exhibit99120190331.htm EXHIBIT 99.1 Exhibit COMPANY CONTACTSShiv KapoorVice President,…
To view the full exhibit click
here
About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)
Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.